Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Go back to Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.21 | 52 Week High | $2.18 | |||
| Open | $10.21 | 52 Week Low | $0.30 | |||
| Day High | $10.21 | P/E | N/A | |||
| Day Low | $10.21 | EPS | $-3.32 | |||
| Volume | 2,404 | |||||
| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.21 | 52 Week High | $2.18 | |||
| Open | $10.21 | 52 Week Low | $0.30 | |||
| Day High | $10.21 | P/E | N/A | |||
| Day Low | $10.21 | EPS | $-3.32 | |||
| Volume | 2,404 | |||||

